Switching to biosimilars could save £1bn over five years, says NHS England
To facilitate cost savings, NHS England is considering making it a new service condition that NHS providers ensure the best-value biosimilar medicines are prescribed.
At least half of the projected savings from switching to biosimilars could be realised by 2028, NHS England says
Shutterstock.com
Switching from original biologic to biosimilar medicines could save the NHS £1bn over five years, NHS England has told The Pharmaceutical Journal.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
